Effect of omega-3 supplementation on neuropathy in type 1 diabetes: A 12-month pilot trial
Lewis EJH, Perkins BA, Lovblom LE, Bazinet RP, Wolever TMS, Bril V
Neurology · 89 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo clínico controlado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2017-05-18 · Neurology · vol. 88 · número 24 · págs. 2294–2301
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 114 citas · más que el 97% de estudios similares · 5.9× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 39 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Fatty Acid Research and Health · Ocular Surface and Contact Lens · Antioxidant Activity and Oxidative Stress
- Palabras clave
- Medicine, Docosapentaenoic acid, Eicosapentaenoic acid, Polyunsaturated fatty acid, Diabetes mellitus, Docosahexaenoic acid, Type 1 diabetes, Diabetic neuropathy, Sensory nerve, Internal medicine, Polyneuropathy, Endocrinology, Fatty acid, Sensory system, Chemistry, Biology, Biochemistry
- MeSH
- animals, seals, earless, humans, diabetic neuropathies, diabetes mellitus, type 1, fatty acids, omega-3, docosahexaenoic acids, eicosapentaenoic acid, fatty acids, unsaturated, oils, treatment outcome, follow-up studies, pilot projects, dietary supplements, middle aged, canada, female, male
6 autores
- Evan J.H. Lewis🇨🇦🇺🇸Mount Sinai Hospital; University Health Network; Sinai Hospital
- Bruce A. Perkins🇨🇦🇺🇸Mount Sinai Hospital; University Health Network; Sinai Hospital
- Leif E. Lovblom🇨🇦🇺🇸Mount Sinai Hospital; University Health Network; Sinai Hospital
- Richard Paul Bazinet🇨🇦🇺🇸Mount Sinai Hospital; University Health Network; Sinai Hospital
- Thomas M. S. Wolever🇨🇦🇺🇸Mount Sinai Hospital; University Health Network; Sinai Hospital
- Vera Bril🇨🇦🇺🇸Mount Sinai Hospital; University Health Network; Sinai Hospital
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objective
To test the hypothesis that 12 months of seal oil omega-3 polyunsaturated fatty acids (ω-3 PUFA) supplementation will stop the known progression of diabetic sensorimotor polyneuropathy (DSP) in type 1 diabetes mellitus (T1DM).
Methods
Individuals with T1DM and evidence of DSP as determined by a Toronto Clinical Neuropathy Score ≥1 were recruited to participate in a single-arm, open-label trial of seal oil ω-3 PUFA supplementation (10 mL·d-1; 750 mg eicosapentaenoic acid, 560 mg docosapentaenoic acid, and 1,020 mg docosahexaenoic acid) for 1 year. The primary outcome was the 1-year change in corneal nerve fiber length (CNFL) measured by in vivo corneal confocal microscopy, with sensory and nerve conduction measures as secondary outcomes.
Results
Forty participants (53% female), aged 48 ± 14 years, body mass index 28.1 ± 5.8 with diabetes duration of 27 ± 18 years, were enrolled. At baseline, 23 participants had clinical DSP and 17 did not. Baseline CNFL was 8.3 ± 2.9 mm/mm2 and increased 29% to 10.1 ± 3.7 mm/mm2 (p = 0.002) after 12 months of supplementation. There was no change in nerve conduction or sensory function.
Conclusions
Twelve months of ω-3 supplementation was associated with increase in CNFL in T1DM.
Clinicaltrialsgovidentifier
NCT02034266.
Classification of evidence
This study provides Class IV evidence that for patients with T1DM and evidence of DSP, 12 months of seal oil omega-3 supplementation increases CNFL.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.